Cernostics, a Pittsburgh, PA-based company focused on delivering next-generation cancer diagnostics and prognostics, raised $2.5m in Series A1 financing.
The round – which has brought total funding to $13m – was led by Illumina Ventures.
The company intends to use the funds to intensify its clinical and market development studies for its assay.
Led by Mike Hoerres, CEO, Cernostics is advancing the TissueCypher® Barrett’s Esophagus Assay, a test that predicts risk of development of esophageal cancer in patients with Barrett’s esophagus, providing actionable information to gastroenterologists, pathologists and patients.
Other backers in the company include UPMC Enterprises, Novitas Capital, Geisinger Health System, the Pittsburgh Life Sciences Greenhouse, and Ben Franklin Technology Partners of Northeastern PA.